SuperworthBioNexus Gene Lab price to book ratio BGLC
Market value divided by the book value of the company's net assets, since 2021.
- Today, Oct 23, 2026
- 0.4×
- 6-year median
- 1.4×
- Against its 6-year history
- 1st
- percentile: 0 is its lowest day, 100 its highest
- 6-year range
- 0.4× to 193×
- Peer median
- 1.0×
BioNexus Gene Lab's price to book ratio is 0.4× as of Oct 23, 2026.
That is below its 6-year median of 1.4×, lower than on 99% of days in the last 6 years.
Over that time it ranged from 0.4× in Jul 2026 to 193× in Mar 2021.
The median for 10 healthcare stocks of a similar size is 1.0×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 0.4× | 0.4× | 1.0× |
| 2025 | 1.1× | 0.4× | 6.2× |
| 2024 | 0.5× | 0.4× | 3.1× |
| 2023 | 1.6× | 1.0× | 28.6× |
| 2022 | 25.7× | 19.5× | 51.7× |
| 2021 | 51.7× | 25.2× | 193× |
Against its peers
Companies in Healthcare nearest BioNexus Gene Lab's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| BGLCBioNexus Gene Lab | 0.4× |
| OXBROXBRIDGE RE HOLDINGS | 1.2× |
| EDUCEducational Development | 0.2× |
| GTIMGood Times Restaurants | 0.4× |
| MDRRMedalist Diversified | 0.6× |
| BCGBinah Capital | 0.9× |
| VIPVulcan Infrastructure & Power | n/m |
| MXCMexco Energy | 1.0× |
| CKXCKX Lands | 1.0× |
| MSGMMotorsport Games | 5.8× |
| ATCHAtlasClear | 1.1× |
| Peer median | 1.0× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on BioNexus Gene Lab
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.